REGN (STOCKS)
Regeneron Pharmaceuticals Inc
$746.460000
-2.410000 (-0.32%)
Prev close: $748.870000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- CEO
- Leonard S. Schleifer
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $78,843.87M
- Employees
- 15,207
- P/E (TTM)
- 18.05
- P/B (TTM)
- 2.53
- Dividend Yield
- 47.81%
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Analyst Recommendations
11
Strong Buy
19
Buy
8
Hold
0
Sell
Recent News
No recent news found for this ticker.
Earnings Surprises
| Period | Actual | Estimate | Surprise | Surprise % |
|---|---|---|---|---|
|
Dec 2025 (Q4)
|
$11.44 | $10.83 | +0.6123 | +5.65% |
|
Sep 2025 (Q3)
|
$11.83 | $9.78 | +2.0500 | +20.96% |
|
Jun 2025 (Q2)
|
$12.89 | $8.61 | +4.2837 | +49.77% |
|
Mar 2025 (Q1)
|
$8.22 | $9.00 | -0.7796 | -8.66% |
Financial Statements
| Revenues | $14.34B |
| Benefits Costs and Expenses | $9.11B |
| Costs And Expenses | $10.77B |
| Nonoperating Income/Loss | $1.65B |
| Operating Expenses | $10.77B |
| Selling, General, and Administrative Expenses | $2.70B |
| Research and Development | $5.85B |
| Other Operating Expenses | $2.21B |
| Operating Income/Loss | $3.58B |
| Income/Loss From Continuing Operations After Tax | $4.50B |
| Income/Loss From Continuing Operations Before Tax | $5.23B |
| Income Tax Expense/Benefit | $725.80M |
| Income Tax Expense/Benefit, Current | $1.51B |
| Income Tax Expense/Benefit, Deferred | -$785.40M |
| Net Income/Loss | $4.50B |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | $4.50B |
| Net Income/Loss Available To Common Stockholders, Basic | $4.50B |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | $43.07 |
| Diluted Earnings Per Share | $41.48 |
| Basic Average Shares | 104,600,000 |
| Diluted Average Shares | 108,600,000 |
| Assets | $40.56B |
| Current Assets | $18.02B |
| Inventory | $3.20B |
| Other Current Assets | $14.82B |
| Noncurrent Assets | $22.54B |
| Intangible Assets | $1.26B |
| Other Non-current Assets | $21.28B |
| Liabilities | $9.30B |
| Current Liabilities | $4.37B |
| Accounts Payable | $939.00M |
| Wages | $773.00M |
| Other Current Liabilities | $2.66B |
| Noncurrent Liabilities | $4.93B |
| Equity | $31.26B |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $31.26B |
| Liabilities And Equity | $40.56B |
| Net Cash Flow From Operating Activities | $4.98B |
| Net Cash Flow From Operating Activities, Continuing | $4.98B |
| Net Cash Flow From Investing Activities | -$629.10M |
| Net Cash Flow From Investing Activities, Continuing | -$629.10M |
| Net Cash Flow From Financing Activities | -$3.72B |
| Net Cash Flow From Financing Activities, Continuing | -$3.72B |
| Exchange Gains/Losses | $300.00K |
| Net Cash Flow | $634.70M |
| Net Cash Flow, Continuing | $634.40M |
| Comprehensive Income/Loss | $4.59B |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | $4.59B |
| Other Comprehensive Income/Loss | $4.59B |
| Other Comprehensive Income/Loss Attributable To Parent | $85.40M |